Forte Biosciences, Inc. (FBRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 7M 14M 21M Q1 '17: 11K Q2 '17: 10K Q3 '17: 10K Q4 '17: 10K Q1 '18: 9K Q2 '18: 9K Q3 '18: 18M Q4 '18: 9K Q1 '19: 9K Q2 '19: 9K Q3 '19: 9K Q4 '19: 9K Q2 '17 Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '16: -7.6M Q2 '16: -7.6M Q3 '16: -8.5M Q4 '16: -8M Q1 '17: -8.6M Q2 '17: -8.7M Q3 '17: -9.7M Q4 '17: -10.7M Q1 '18: -12.8M Q2 '18: -15.3M Q3 '18: 1.4M Q4 '18: -19.1M Q1 '19: -16.9M Q2 '19: -629K Q3 '19: -684K Q1 '20: -2M Q2 '20: -34.8M Q3 '20: -5M Q4 '20: -4.5M Q1 '21: -4.7M Q2 '21: -5.7M Q3 '21: -7.7M Q4 '21: -3.3M Q1 '22: -2.5M Q2 '22: -3M Q3 '22: -3.4M Q4 '22: -4.9M Q1 '23: -6.9M Q2 '23: -9M Q3 '23: -10.2M Q4 '23: -6.4M Q1 '24: -7.8M Q2 '24: -12.8M Q3 '24: -8.6M Q4 '24: -7.4M Q1 '25: -16.1M Q2 '25: -11.6M Q3 '25: -18.4M Q4 '25: -24.6M Q1 '26: -22.4M Q2 '26: -24.6M Q1 '17 Q3 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '16: -8M Q2 '16: -8M Q3 '16: -9M Q4 '16: -8.4M Q1 '17: -9.1M Q2 '17: -9.1M Q3 '17: -10M Q4 '17: -10.8M Q1 '18: -12.9M Q2 '18: -16.1M Q3 '18: -383K Q4 '18: -19.6M Q1 '19: -1.2M Q2 '19: -630K Q3 '19: -690K Q4 '19: -10.6M Q1 '20: -2M Q2 '20: -34.8M Q3 '20: -5.1M Q4 '20: -4.6M Q1 '21: -4.8M Q2 '21: -5.8M Q3 '21: -7.8M Q4 '21: -3.3M Q1 '22: -2.6M Q2 '22: -3M Q3 '22: -3.4M Q4 '22: -4.9M Q1 '23: -6.8M Q2 '23: -8.9M Q3 '23: -10M Q4 '23: -5.9M Q1 '24: -7.4M Q2 '24: -12.5M Q3 '24: -8.4M Q4 '24: -7.2M Q1 '25: -15.7M Q2 '25: -11.2M Q3 '25: -17.7M Q4 '25: -24.8M Q1 '26: -22.1M Q2 '26: -23.3M Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '16: -6.1M Q2 '16: -7.8M Q3 '16: -7.9M Q4 '16: -7.7M Q1 '17: -7.6M Q2 '17: -7.4M Q3 '17: -7M Q4 '17: -9.2M Q1 '18: -12.7M Q2 '18: -10.8M Q3 '18: 945K Q4 '18: -11.9M Q1 '19: -17.7M Q2 '19: 16.1M Q3 '19: -553K Q4 '19: -653K Q1 '20: -2.9M Q2 '20: -4M Q3 '20: -7.7M Q4 '20: -3.8M Q1 '21: -4M Q2 '21: -3.9M Q3 '21: -5.1M Q4 '21: -3.6M Q1 '22: -2M Q2 '22: -1.4M Q3 '22: -1.9M Q4 '22: -2.9M Q1 '23: -5.2M Q2 '23: -5.5M Q3 '23: -9.1M Q4 '23: -9M Q1 '24: -6.7M Q2 '24: -5.9M Q3 '24: -8.1M Q4 '24: -10M Q1 '25: -10.4M Q2 '25: -10.1M Q3 '25: -14M Q4 '25: -16.5M Q1 '26: -18.8M Q2 '26: -22.7M Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '16: -6.1M Q2 '16: -7.9M Q3 '16: -8.3M Q4 '16: -7.8M Q1 '17: -7.6M Q2 '17: -7.4M Q3 '17: -7.3M Q4 '17: -9.5M Q1 '18: -12.9M Q2 '18: -11.4M Q3 '18: 326K Q4 '18: -12.4M Q1 '19: -17.8M Q2 '19: 16M Q3 '19: -737K Q4 '19: -742K Q4 '23: -9M Q1 '24: -6.7M Q2 '24: -5.9M Q3 '24: -8.1M Q4 '24: -10M Q1 '25: -10.4M Q2 '25: -10.1M Q3 '25: -14.1M Q4 '25: -16.5M Q1 '26: -18.8M Q2 '26: -22.7M Q3 '16 Q3 '17 Q3 '18 Q3 '19 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8M 16M 24M Q2 '21: 13.6M Q3 '21: 14.2M Q1 '22: 14.8M Q2 '22: 14.8M Q3 '22: 18.9M Q1 '23: 21M Q2 '23: 21M Q2 '21 Q3 '21 Q1 '22 Q2 '22 Q3 '22 Q1 '23 Q2 '23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-750.00 -500.00 -250.00 0.00 250.00 500.00 750.00 Q4 '16: -15.22 Q1 '17: -15.69 Q2 '17: -12.59 Q3 '17: -9.00 Q4 '17: -5.72 Q1 '18: -2.26 Q2 '18: -2.51 Q3 '18: -2.03 Q4 '18: -2.44 Q1 '19: -2.53 Q2 '19: -301.72 Q3 '19: -631.70 Q4 '19: -631.19 Q1 '20: -631.42 Q2 '20: -340.94 Q3 '20: -11.39 Q4 '21: -1.54 Q1 '22: -1.35 Q2 '22: -1.13 Q3 '22: -0.77 Q4 '22: -0.80 Q1 '23: -0.95 Q2 '23: -1.16 Q3 '23: -7.55 Q4 '23: -8.26 Q1 '24: -11.97 Q2 '24: -18.33 Q3 '24: -16.30 Q4 '24: -12.17 Q1 '25: -9.51 Q2 '25: -3.69 Q3 '25: -0.14 Q4 '25: -4.77 Q1 '26: -4.64 Q2 '26: -4.65 Q4 '17 Q1 '19 Q2 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.